Did You Know?

Editor’s Picks

Latest News

Inimmune Presents Late-Breaking Phase 1 INI-4001 Results Demonstrating On-Target Immune Activation in Advanced Solid Tumors at SITC 2026

Study demonstrated no dose-limiting toxicities and dose-responsive cytokine production consistent with TLR7/8 engagementResults support continued clinical development of INI-4001 as...

error: Content is protected !!